| Code | CSB-RA868278MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Guselkumab, designed to specifically target IL23A (Interleukin-23 subunit alpha), also known as p19. IL23A combines with IL12B to form the heterodimeric cytokine IL-23, which plays a critical role in inflammatory and immune responses by promoting the differentiation and survival of Th17 cells. This cytokine pathway is centrally involved in the pathogenesis of various autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and inflammatory bowel disease. Dysregulated IL-23 signaling contributes to chronic inflammation and tissue damage in these disorders.
Guselkumab is a fully humanizedized IgG1λ monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. By selectively binding to the p19 subunit of IL-23, it prevents the cytokine from interacting with its receptor, thereby inhibiting IL-23-mediated inflammatory pathways. This biosimilar antibody serves as a valuable research tool for investigating IL-23 biology, studying immune-mediated inflammatory diseases, evaluating therapeutic mechanisms, and developing novel treatment strategies targeting the IL-23/Th17 axis.
There are currently no reviews for this product.